For laboratory research use only. Not for human consumption.

Neuro SeriesNeuropeptide Research

Semax

ACTH 4-10 Analog Heptapeptide

Semax is a synthetic heptapeptide analog of ACTH 4-10, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. By modifying the 4-10 fragment of adrenocorticotropic hormone, researchers created a compound that retains neurotropic activity while eliminating hormonal effects on cortisol production. Decades of published research — primarily in Russian scientific literature — have examined its interactions with neurotrophic factor expression and cognitive processing pathways.

Why Researchers Study It

Semax is studied because it bridges two areas that rarely overlap: melanocortin receptor pharmacology and neurotrophic factor signaling. The 2006 discovery that it regulates BDNF and TrkB expression gave researchers a molecular mechanism connecting a synthetic peptide to endogenous pathways central to modern neuroscience.

Neurotrophic Factor Expression

Published research has documented that Semax increases BDNF and TrkB receptor expression in hippocampus and cortex, establishing a key molecular mechanism.

Cognitive & Attention Research

Studies have examined Semax's effects on attention, memory, and learning processes, noting modulation of dopaminergic and serotonergic systems.

Neuroprotective Pathways

Research in experimental stroke and brain injury models has documented effects on gene expression patterns associated with inflammation and neuronal survival.

Transcriptomic Profiling

Gene expression studies revealed Semax affects hundreds of genes in brain tissue, including those involved in immune response and neurotransmitter metabolism.

Research Timeline

8 milestones spanning 1982–2020

Key Milestones
  • Synthesized as a modified ACTH 4-10 fragment at the Russian Academy of Sciences (1982–1985)
  • Landmark BDNF regulation study published in Brain Research (2006)
  • Transcriptomic profiling revealed hundreds of affected genes (2013–2015)

Published Research

Selected citations from the published literature.

Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression. Brain Res. 2006;1117(1):54-60

Ashmarin IP, et al. Nootropic and analgesic effects of Semax. Zh Vyssh Nerv Deiat Im I P Pavlova. 2001;51(4):420-426

Research Use Compliance

All information presented on this page references published preclinical research and is provided for educational and informational purposes only. These products are intended for laboratory research use only. Not for human consumption. No statements on this page have been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.